Tejara Capital Ltd Reduces Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Tejara Capital Ltd decreased its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 12.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 4,661,547 shares of the biotechnology company's stock after selling 644,269 shares during the period. Heron Therapeutics makes up 4.6% of Tejara Capital Ltd's holdings, making the stock its 8th largest position. Tejara Capital Ltd owned 3.06% of Heron Therapeutics worth $7,132,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Argent Advisors Inc. bought a new stake in shares of Heron Therapeutics during the 4th quarter valued at $31,000. CM Management LLC increased its position in shares of Heron Therapeutics by 40.0% in the 4th quarter. CM Management LLC now owns 700,000 shares of the biotechnology company's stock valued at $1,071,000 after buying an additional 200,000 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Heron Therapeutics in the 4th quarter valued at $208,000. Charles Schwab Investment Management Inc. increased its position in shares of Heron Therapeutics by 0.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company's stock valued at $1,692,000 after buying an additional 9,418 shares in the last quarter. Finally, Anfield Capital Management LLC increased its position in shares of Heron Therapeutics by 5.6% in the 4th quarter. Anfield Capital Management LLC now owns 118,976 shares of the biotechnology company's stock valued at $182,000 after buying an additional 6,264 shares in the last quarter. Institutional investors own 80.01% of the company's stock.

Remove Ads

Heron Therapeutics Stock Performance

NASDAQ HRTX traded down $0.02 on Friday, reaching $2.38. The company had a trading volume of 1,468,543 shares, compared to its average volume of 2,357,348. The firm has a market capitalization of $362.55 million, a price-to-earnings ratio of -13.22 and a beta of 1.55. Heron Therapeutics, Inc. has a 1-year low of $1.04 and a 1-year high of $3.93. The company's fifty day moving average is $1.92 and its 200-day moving average is $1.76.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.05. The company had revenue of $40.78 million during the quarter, compared to analyst estimates of $37.37 million. On average, research analysts forecast that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

HRTX has been the subject of a number of recent analyst reports. StockNews.com cut shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. Needham & Company LLC restated a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research report on Friday, February 28th.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.